A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.

Item
http://www.wikidata.org/entity/Q33586505
Bortezomib for the treatment of multiple myelomaFifty years of melphalan use in hematopoietic stem cell transplantationRetinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cellsArsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6Bortezomib in multiple myeloma: systematic review and clinical considerations.Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies.Not too little, not too much-just right! (Better ways to give high dose melphalan).Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.Opposing effects of low versus high concentrations of water soluble vitamins/dietary ingredients Vitamin C and niacin on colon cancer stem cells (CSCs).Bayesian survival analysis in clinical trials: What methods are used in practice?Induction of cellular and molecular Immunomodulatory pathways by vitamin E and vitamin C.Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid.Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
P2860

A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.

Item
http://www.wikidata.org/entity/Q33586505
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@ast
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@en
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@nl
type
label
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@ast
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@en
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@nl
prefLabel
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@ast
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@en
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932